A systematic review and network meta-analysis to evaluate the comparative efficacy of interventions for unfit patients with chronic lymphocytic leukemia by Städler, Nicolas et al.
ORIGINAL RESEARCH
A Systematic Review and Network Meta-Analysis
to Evaluate the Comparative Efficacy of Interventions
for Unfit Patients with Chronic Lymphocytic
Leukemia
Nicolas Sta¨dler . Aijing Shang . Francesc Bosch . Andrew Briggs .
Valentin Goede . Aurelien Berthier . Corinne Renaudin . Veronique Leblond
Received: May 27, 2016 / Published online: August 17, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Rituximab plus fludarabine and
cyclophosphamide (RFC) is the standard of care
for fit patients with untreated chronic
lymphocytic leukemia (CLL); however, its use
is limited in ‘unfit’ (co-morbid and/or full-dose
F-ineligible) patients due to its toxicity profile.
We conducted a systematic review and Bayesian
network meta-analysis (NMA) to determine the
relative efficacy of commercially available
interventions for the first-line treatment of
unfit CLL patients.
Methods: For inclusion in the NMA, studies
had to be linked via common treatment
comparators, report progression-free survival
(PFS), and/or overall survival (OS), and meet at
least one of the five inclusion criteria: median
cumulative illness score [6, median creatinine
clearance B70 mL/min, existing co-morbidities,
median age C70 years, and no full-dose F in the
comparator arm. A manual review, validated by
external experts, of all studies that met at least
one of these criteria was also performed to
confirm that they evaluated first-line
therapeutic options for unfit patients with CLL.
Results: In unfit patients, the main NMA (five
studies for PFS and four for OS) demonstrated
clear preference in terms of PFS for
obinutuzumab ? chlorambucil (G-Clb) versus
rituximab ? chlorambucil (R-Clb),
ofatumumab ? chlorambucil (O-Clb),
fludarabine and chlorambucil (median hazard
ratios [HRs] 0.43, 0.33, 0.20, and 0.19,
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respectively), and a trend for better efficacy
versus rituximab ? bendamustine (R-Benda)
and RFC-Lite (median HR 0.81 and 0.88,
respectively). OS results were generally
consistent with PFS data, (median HR 0.48,
0.53, and 0.81, respectively) for G-Clb versus
Clb, O-Clb, and R-Clb 0.35 and 0.81 versus F
and R-Benda, respectively); however, the OS
findings were associated with higher
uncertainty. Treatment ranking reflected
improved PFS and OS with G-Clb over other
treatment strategies (median rank of one for
both endpoints).
Conclusion: G-Clb is likely to show superior
efficacy to other treatment options selected in
our NMA for unfit treatment-naı¨ve patients
with CLL.
Funding: F. Hoffmann-La Roche Ltd.
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INTRODUCTION
Rituximab in combination with fludarabine and
cyclophosphamide (RFC) is currently the
standard of care for medically fit patients with
previously untreated chronic lymphocytic
leukemia (CLL) [1–3]. However, many patients
with CLL are in their 70’s and beyond before
they need to start treatment, and are likely to
have a greater co-morbidity burden [4]. For this
often medically unfit population, RFC is
unsuitable, with data from several clinical
studies suggesting that the regimen is
associated with excessive toxicity (e.g.,
cytopenias and increased infection rates)
relative to the remission rates achieved [5, 6].
Other therapeutic options are available for unfit
patients with CLL and include chlorambucil
(Clb) in combination with an anti-CD20
antibody such as rituximab (R-Clb),
obinutuzumab (G-Clb) or ofatumumab
(O-Clb), rituximab in combination with
bendamustine (R-Benda), dose-reduced
fludarabine with cyclophosphamide (FC), and
a dose-modified RFC regimen (RFC-Lite)
[2–4, 7–10]. Available data from randomized
controlled trials (RCTs) suggest an
improvement in efficacy with certain regimens
in this setting. For example, significant
improvements in progression-free survival
(PFS) have been reported in unfit patients with
CLL with R-Benda compared with R-Clb in the
MaBLe study (median PFS 39.6 versus
29.9 months; hazard ratio [HR] 0.523; 95%
confidence interval [CI] 0.339–0.806;
P = 0.003) [10], and with G-Clb compared
with the equivalent rituximab regimen in the
CLL11 study (29.2 versus 15.4 months; HR 0.40;
95% CI 0.33–0.50; P\0.001) [11]; however,
with a limited number of head-to-head
treatment comparisons available, the optimal
treatment for unfit patients with CLL remains
unclear.
Network meta-analysis (NMA) allows
information from direct head-to-head studies
to be combined with information from indirect
treatment comparisons to enable estimation of
the comparative efficacy of therapies and build
a hierarchy of available treatments [12, 13].
Furthermore, the outputs of NMA-based
comparative effectiveness research can be used
in a full economic appraisal of competing
interventions to assess the cost-effectiveness
[14]. The usefulness of NMA has been
demonstrated across a range of therapeutic
interventions and disease areas including CLL
[15–20]. Naı¨ve comparison of drug treatments
Adv Ther (2016) 33:1814–1830 1815
based on data from different studies carries with
it a risk of making incorrect conclusions; by
assuming the constancy of relative treatment
effects (odds ratios or HRs) to link studies, NMA
minimizes this risk. We, therefore, conducted a
systematic review and Bayesian NMA of data
from all RCTs comparing at least two
interventional treatments in patients
presenting with ‘first-line’ CLL and/or who
were not eligible to receive full-dose
fludarabine (F) to determine the relative effects
of treatments on PFS and overall survival (OS).
METHODS
Data Source and Searches
We conducted an initial literature search plus
two updates of five databases (Embase,
Medline, Medline In-Process, the Cochrane
Database of Systematic Reviews [CDSR], and the
Database of Abstracts of Reviews of Effects
[DARE]) to identify RCTs investigating
first-line treatment in CLL published between
January 1992 and August 2015. Search terms
included the names of drugs used as first-line
treatment for CLL combined with the Medical
Subject Heading (MeSH) term ‘Leukemia,
lymphocytic, chronic, B-cell’ (see
supplementary material, section A for search
strategies used). In addition to the above
searches, abstracts from the proceedings of
selected conferences (American Society of
Clinical Oncology, American Society of
Hematology, European Hematology
Association) held between March 2010 and
August 2015 were hand-searched.
ClinicalTrials.gov (US National Institute of
Health), the World Health Organization’s
(WHO) meta-registry, the International
Clinical Trials Registry Platform Search Portal,
and the Cochrane Central Register of
Controlled Trials were searched for trials in
progress. Bibliographic searching of included
trials and systematic reviews was also
performed. Language of publication was
restricted to English.
Study Selection
The systematic literature search and screening
process for trials are described in section B of the
supplementary material. Two independent
reviewers screened the titles and abstracts of
all identified studies to produce a list of
potentially relevant studies. They then
performed a detailed screening of the full-text
versions of these studies to identify the final list
of studies for consideration in the analysis.
When reviewing the full text, the objective was
to identify whether the study inclusion criteria
allowed for the enrollment of patients with
co-morbidities, such as renal impairment. In
addition, during the same full-text review, the
baseline characteristics of patients included in
the studies were reviewed to identify (if any) the
level of co-morbidities. Any discrepancies in the
decisions of the two reviewers were resolved by
a third independent reviewer.
Studies selected for inclusion in the NMA
were RCTs comparing first-line treatment in
patients with CLL. Also, included studies had to
be linked via common treatment comparators,
to report PFS and/or OS data, and were required
to meet at least one of five ‘co-morbidity’
inclusion criteria in descending sequence
priority: a median cumulative illness rating
score (CIRS) of [6, median creatinine
clearance B70 mL/min, existing co-morbidities
(particularly relating to renal impairment),
median age C70 years, and/or no full-dose F in
the comparator arm. These five criteria served as
the basis for the identification of publications in
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the literature that may have evaluated first-line
treatments for co-morbid/unfit patients with
CLL. A final manual review of all the studies
that met at least one of these five criteria was
performed and then validated by external
experts in the field of CLL, to confirm whether
the identified studies did, in fact, evaluate the
first-line therapeutic options for co-morbid/unfit
and/or full-dose F-ineligible patients with CLL.
Data Extraction and Statistical Analysis
For each selected trial, unadjusted HRs for PFS
and OS were extracted into a pre-defined
extraction grid to ensure that the data were
extracted uniformly and were comparable
across studies. Data were independently
extracted by two analysts, with their results
checked and reconciled by a third-party
independent analyst. If HR data were not
reported, HRs were estimated using a method
that was appropriate for the available published
PFS/OS statistic. For example, if the median PFS/
OS was reported, an exponential distribution
was assumed and the HR was estimated as the
ratio of the median PFS/OS time for the two
treatment arms [21]. In papers where landmark
PFS/OS data were reported (e.g., 3-year PFS),
proportionality of hazard functions was
assumed and the HR was calculated as
HR = lnS1(t)/lnS0(t), where S0(t) and
S1(t) denote survival estimates at time t for the
control and treatment arm, respectively. In only
two of the trials, HRs were not reported and
were estimated.
NMA as presented in this manuscript was
based on the natural logarithms of the HRs
(lnHR) and standard deviations (SDs). Published
CIs or log-rank P values (in two cases where HRs
values were not reported) were used to estimate
SDs for lnHRs [22].
Network Meta-Analysis
The NMA was conducted using a hierarchical,
contrast-based model where lnHRi of trial
i follows a normal distribution centered at the
(unknown) treatment effect with an SD equal to
SDi. To deal with three-arm trials, we followed
the approach described by Dias et al. [23]. Fixed
effects (FE) and random effects (RE) models were
explored. The latter accounted for
between-study variation using a heterogeneity
parameter s.
The NMA was performed for PFS and OS on
two different evidence networks: the main
analysis was based on a network of five studies
for PFS and four studies for OS, which were
selected according to the five pre-defined
criteria and expert opinion (base-case analysis);
an additional analysis was also conducted based
on a secondary evidence network that included
an additional three studies (i.e., a total of eight
studies for PFS and seven studies for OS that met
at least one of the five pre-defined criteria [no
expert involvement]).
Model inference was conducted within a
Bayesian framework (see supplementary
material, section C for the full BUGS code)
[24]. The posterior distributions of the model
parameters were obtained using Markov Chain
Monte Carlo (MCMC) methods implemented in
the software JAGS [25]. All analyses were
performed using the computing environment
R. The R package ‘‘R2jags’’ was used for MCMC
simulations. Using three chains, the first 10,000
simulations, with a thinning rate of 500, were
discarded as burn-in. Parameters were then
monitored for a further 1 million simulations,
with the same value of thinning, resulting in a
total of 2000 MCMC samples per chain.
Convergence of the chains was confirmed
using trace plots, density plots of treatment
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effects, and the Gelman and Rubin’s diagnostic
statistic [24].
For the FE model, the heterogeneity
parameter s was assumed to be zero, and all
other relevant parameters were equipped with
flat priors. For the RE model, a half-normal prior
of the form s* HN[(su/1.96)
2] was considered
[26]. This prior has its mode at 0 and is steadily
declining in s, with an upper 95% point at su.
We set su at 0.25, which yields an informative
prior (a heterogeneity parameter of su = 0.25
translates to HRs ranging from 0.61 to 1.63
[26]). We note that uninformative priors on s
are not appropriate in this setting as most
comparisons are informed by a single study
(see ‘‘Results’’).
All results were reported as median posterior
HRs with corresponding 95% credible intervals
(CrIs). The treatments were ranked in each
MCMC simulation, and medians and 95% CrIs
of the posterior ranks were reported. Further,
posterior probabilities of being the best
treatment were obtained as the proportion of
simulations in which each treatment had the
smallest HR.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
Systematic Review and Included Studies
The initial literature search and two updates
yielded 244 citations published between
January 1992 and August 2015
(supplementary material, section B).
Following screening and examination of the
papers, we selected a total of eight RCTs that
met at least one of the five pre-defined
criteria: CLL11, CLL5, COMPLEMENT 1,
Nikitin, MaBLe, Knauf, CAM307, and
CALGB9011 [8–10, 27–31]. According to
expert feedback, three of the studies, Knauf,
CAM307, and CALGB9011, did not match the
typical unfit patient scenario and were
considered to have included patients who
were more fit compared with the other RCTs.
Table 1 summarizes the main characteristics
of the included studies. The treatments
evaluated in the eight studies included four
single agents: F (in two treatment arms), Clb (six
treatment arms), alemtuzumab (Alm; one
treatment arm) and bendamustine (Benda; one
treatment arm), and five combination
regimens: G-Clb (one treatment arm), R-Clb
(three treatment arms), R-Benda (one treatment
arm), RFC-Lite (one treatment arm) and O-Clb
(one treatment arm). Eight RCTs reported PFS,
and six RCTs reported OS (Cam307 and Nikitin
did not report OS). Treatment effects in terms of
PFS and OS for the eight studies are summarized
in Table 2.
Network Meta-Analysis
Figure 1 summarizes the network geometries
for PFS and OS, showing the included studies
and direct treatment comparisons. The studies
excluded in accordance with expert opinion
are highlighted in red. We consider a full
network of eight RCTs (eight for PFS, seven for
OS) and a reduced network of five RCTs (trials
excluded in accordance with expert opinion;
five for PFS, four for OS). The analysis
performed on the reduced network represents
our main analysis; the full network was used
for completeness in an additional analysis.
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Main Analysis
Forest plots displaying median HRs and CrIs for
PFS and OS for the different treatments
compared with G-Clb are shown in Fig. 2 for
the main analysis, FE model, of five RCTs. For
the clinical endpoint of PFS, the FE NMA model
showed a preference for G-Clb compared with
R-Clb, O-Clb, F, and Clb; the CrIs for these data
were relatively narrow and all median HR values
were substantially \1 (0.43, 0.33, 0.20, and
0.19, respectively). Also, there was a trend for
better efficacy for G-Clb over R-Benda and
RFC-Lite in terms of PFS, with HRs of 0.81 and
0.88, respectively. Comparable results were also
observed when between-study heterogeneity
was accounted for using an RE model with an
informative prior (uninformative priors are not
appropriate here as all comparisons are
informed by a single study). Using this
approach, median HR values for PFS were
within the same range for G-Clb compared
with R-Clb, O-Clb, F, and Clb (0.43, 0.33, 0.20,
and 0.19, respectively) and 0.81 and 0.88,
respectively, for G-Clb versus R-Benda and
RFC-Lite. As expected, the RE model led to
Fig. 1 Network of trials and treatments selected using the
ﬁve ‘ﬂudarabine-ineligibility’ criteria a PFS and b OS. The
main analysis excluded the three studies highlighted in red
(expert recommendation). The additional analysis is based
on the whole network. Alm alemtuzumab, Benda
bendamustine, Clb chlorambucil, F ﬂudarabine, G-Clb
obinutuzumab ? chlorambucil, O-Clb ofatumumab ?
chlorambucil, OS overall survival, PFS progression-free
survival, R-Benda rituximab ? bendamustine, R-Clb
rituximab ? chlorambucil, RFC rituximab ? ﬂudarabine
? cyclophosphamide
Fig. 2 Main analysis (Knauf, Cam307, and Calgb_9011
excluded): effect of interventional treatments on a PFS and
b OS using a FE model. Forest plots show relative effect of
each treatment on PFS and OS as compared with the
reference combination treatment G-Clb. Median HRs and
CrIs are shown. Clb chlorambucil, CrI credible interval,
F ﬂudarabine, FE ﬁxed effects, G-Clb obinutuzumab ?
chlorambucil, HR hazard ratio, O-Clb ofatumumab ?
chlorambucil, OS overall survival, PFS progression-free
survival, R-Benda rituximab ? bendamustine, R-Clb
rituximab? chlorambucil, RFC rituximab ? ﬂudarabine ?
cyclophosphamide
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wider CrIs. Data for the main analysis using the
RE model are summarized in the supplementary
material, sections D and E.
OS results were generally consistent with the
PFS results, suggesting greater efficacy for G-Clb
over other treatments. Using the FE model,
there was a preference for G-Clb compared with
Clb, O-Clb, and R-Clb (median HR 0.48, 0.53,
and 0.81, respectively, and relatively narrow
CrIs) and a trend for better efficacy for G-Clb
versus F and R-Benda (median HR 0.35 and 0.81,
respectively; Fig. 2). These findings also held
true for the RE model (supplementary material,
sections D and E). However, due to fewer OS
events, the CrIs for these data, using both the FE
and RE models, were considerably wider than
for the PFS data, suggesting that there was
greater uncertainty associated with the OS data.
For example, the large CrI for G-Clb versus F (FE
model: HR 0.35, CrI 0.07, 1.86; RE model: HR
0.34, CrI 0.06, 1.93) was driven by an SD of
0.812 from the CLL5 trial (Table 2).
Treatment ranking reflected the
improvement in PFS and OS associated with
G-Clb over other treatment strategies (median
rank 1 for both), and also indicated that G-Clb
had a higher probability of being the favored
therapy using both the FE model (PFS 56%
[median rank 1, CrI 1, 3]; OS 57% [median rank
1, CrI 1, 4]; Table 3) and the RE model (PFS 53%
[median rank 1, CrI 1, 3]; OS 55% [median rank
1, CrI 1, 4]; supplementary material, sections D
and E).
Additional Analysis
The analysis was repeated on all eight trials
identified using the five F-ineligibility criteria
(no expert assessment). Inclusion of an
additional three studies made minimal
difference to the estimated treatment effects
and the rank ordering of treatments (Fig. 3;
Table 4). These findings for the additional
analysis were consistent for both the FE and
RE models. Data for the additional analysis
using the RE model are summarized in the
supplementary material, sections D and E.
For OS, of note was the narrower CrI for the
comparison of G-Clb versus F (FE model: HR
0.57, CrI 0.34, 0.95) compared with the wide
CrI presented earlier in the main analysis. The
higher precision in the additional analysis is a
consequence of the combined evidence from
the CLL5 and CALGB9011 trials.
Table 3 Main analysis: treatment ranking for PFS and OS
Outcome/treatment
regimen
Fixed effects model
Probability
best
Median
rank (CrI)
PFS
G-Clb 0.56 1 (1, 3)
RFC-Lite 0.3 2 (1, 3)
R-Benda 0.15 3 (1, 3)
R-Clb 0 4 (4, 5)
O-Clb 0 5 (4, 5)
F 0 6 (6, 7)
Clb 0 7 (6, 7)
OS
G-Clb 0.57 1 (1, 4)
R-Benda 0.25 3 (1, 6)
R-Clb 0.07 3 (1, 4)
O-Clb 0.02 4 (2, 6)
Clb 0 5 (3, 6)
F 0.09 6 (1, 6)
Analysis excludes studies Knauf [29], Cam307 [30], and
Calgb_9011 [31] (expert recommendation)
Clb chlorambucil, CrI credible interval, F ﬂudarabine,
G-Clb obinutuzumab ? chlorambucil, O-Clb ofatumumab
? chlorambucil, OS overall survival, PFS progression-free
survival, R-Benda rituximab ? bendamustine, R-Clb
rituximab ? chlorambucil, RFC rituximab ? ﬂudarabine
? cyclophosphamide
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Differences in terms of PFS efficacy were
observed among chemotherapies, with Benda
showing greater efficacy compared with F, Clb,
and Alm; HRs were 0.35 (Benda versus Clb), and
0.61 (Benda versus Alm) using both the FE and
RE models, and were 0.46 and 0.45 for Benda
versus F using the FE and RE models,
respectively (supplementary material, sections
D and E).
DISCUSSION
This NMA evaluating the relative efficacy of
therapeutic interventions for the first-line
treatment of unfit patients with CLL produced
a number of key findings. Consistently, for both
efficacy endpoints (PFS and OS) and all
scenarios, our results suggest that therapy
comprising a combination of the anti-CD20
monoclonal antibody obinutuzumab and
Fig. 3 Additional analysis (Knauf, Cam307, and
Calgb_9011 included): effect of interventional treatments
on a PFS and b OS using a FE model. Forest plots show
relative effect of each treatment on PFS and OS as
compared with the reference combination treatment
G-Clb. Median HRs and CrIs are shown. Alm
alemtuzumab, Benda bendamustine, Clb chlorambucil,
CrI credible interval, F ﬂudarabine, FE ﬁxed effects, G-Clb
obinutuzumab ? chlorambucil, HR hazard ratio, O-Clb
ofatumumab ? chlorambucil, OS overall survival, PFS
progression-free survival, R-Benda rituximab ?
bendamustine, R-Clb rituximab ? chlorambucil, RFC
rituximab ? ﬂudarabine ? cyclophosphamide
Table 4 Additional analysis: treatment ranking for PFS
and OS
Outcome/treatment
regimen
Fixed effects model
Probability
best
Median
rank (CrI)
PFS
G-Clb 0.55 1 (1, 3)
RFC-Lite 0.3 2 (1, 4)
R-Benda 0.15 3 (1, 4)
Benda 0 4 (3, 5)
R-Clb 0 5 (4, 6)
O-Clb 0 6 (5, 8)
Alm 0 7 (5, 8)
F 0 8 (7, 8)
Clb 0 9 (9, 9)
OS
G-Clb 0.61 1 (1, 4)
R-Benda 0.27 3 (1, 7)
R-Clb 0.07 3 (1, 5)
Benda 0.03 4 (1, 7)
O-Clb 0.01 5 (2, 7)
F 0 5 (3, 7)
Clb 0 6.5 (5, 7)
Studies Knauf [29], Cam307 [30], and Calgb_9011 [31]
included in analysis
Alm alemtuzumab, Benda bendamustine, Clb
chlorambucil, CrI credible interval, F ﬂudarabine, G-Clb
obinutuzumab ? chlorambucil, O-Clb ofatumumab ?
chlorambucil, OS overall survival, PFS progression-free
survival, R-Benda rituximab ? bendamustine, R-Clb
rituximab ? chlorambucil, RFC rituximab ?
ﬂudarabine ? cyclophosphamide
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chlorambucil (G-Clb) is likely to be superior to
many other treatment options including Benda,
R-Clb, O-Clb, Alm, F, and Clb in unfit patients
with CLL. In addition, G-Clb showed a trend for
greater efficacy over the regimens RFC-Lite and
R-Benda in this setting. Our results for OS were
generally consistent with the data on PFS,
suggesting beneficial outcomes with G-Clb
over other regimens, and were driven by the
consistent trend in OS favoring G-Clb in the
CLL-11 trial [11, 27, 32]. However, the OS data
in our study were associated with greater
uncertainty, and this was not unexpected
given that the follow-up times for OS were
relatively short. We also note that to the best of
our knowledge, PFS has not yet been validated
as a surrogate endpoint for OS in the first-line
treatment of unfit patients with CLL within a
meta-analytic framework [33].
Our NMA of PFS (additional analysis) also
supported the findings of the Knauf study
suggesting that Benda is a more potent
chemotherapy, leading to ‘deeper’ remission
than the traditional agent Clb in unfit patients
[29]. Given this finding, it was of interest to
note a trend favoring the combination of
obinutuzumab with Clb over rituximab
combined with Benda, as shown by the HR
estimate for PFS (0.81 CrI 0.49, 1.33).
Through the use of pre-defined ‘co-morbidity’
inclusion criteria combined with expert review,
we were able to restrict our analysis to unfit
patients with CLL who were likely to meet the
unfit definition as described in the CLL11 trial
[27]. However, information on CLL patient
‘fitness’/CIRS is not always reported in the
literature, making it difficult to evaluate a study
population’s level of fitness/co-morbidity;
moreover, there is no well-defined surrogate
marker for fitness status/co-morbidity. To
address this, we used five pre-defined
co-morbidity criteria (median CIRS[6, median
CrCL B70 mL/min, existing co-morbidities,
median age C70 years, and no full-dose F in the
comparator arm) to approximate the level of
patient fitness/co-morbidity indirectly in each
study. Because of the potential heterogeneity of
the identified papers, a manual review of the full
text of the identified papers was conducted, and
the final selection of papers was approved by
experts. This final selection led to the exclusion
of the following studies from the main analysis:
Cam307 (study inclusion criteria included
adequate renal and liver function and median
age was 59–60 years) [30], Calgb_9011 (F dose
appeared to be the full dose, 20 or 25 mg/m2
intravenously days 1–5 every 28 days) [31], and
Knauf (a high percentage of patients in both the
Benda [70%] and Clb [65%] arms had a WHO
performance score of 0 and a median age of
approximately 65 years, therefore, it was
unlikely that the patients included were not
eligible for full-dose F) [29]. It is also important to
note that the three excluded studies were
conducted at a time when Clb (rather than
RFC) was the standard of care even in fit
patients, since at that time, no treatment had
shown an OS benefit over Clb. Also, these studies
were not designed to explicitly enroll unfit
patients, their median age was substantially
lower than the remaining five studies, and
chemotherapy alone is not currently considered
a relevant treatment option (even in unfit CLL).
An important advantage of NMA over naı¨ve
inter-trial comparisons is that the calculations
are based on relative treatment effects (in terms
of HRs) rather than absolute effects. Thereby,
NMA circumvents the potential
incomparability of two studies due to
differences in the distributions of measured
and/or unmeasured prognostic factors. For
example, a naı¨ve comparison of the R-Benda
arm in MaBLe (median PFS 39.6 months) [10]
with the G-Clb arm in CLL11 (median PFS
1824 Adv Ther (2016) 33:1814–1830
29.2 months) [11] would have led to the
opposite conclusion of better performance of
R-Benda versus G-Clb. This naı¨ve comparison
compares efficacy on an ‘absolute’ scale and
ignores the fact that the common comparator
R-Clb in these two studies showed substantial
discrepancy in terms of median PFS
(29.9 months in MaBLe and 15.4 months in
the CLL11 study, respectively). The prognostic
differences that lead to this study bias between
MaBLe and CLL11 may be manifold with
differences in methodology of data generation
and data read-out as the main drivers. We note
that our NMA does not account for potential
effect modifiers, which are defined as patient or
study characteristics that influence the two
treatment arms to a different extent and,
therefore, alter the relative treatment effect. A
speculative effect modifier could be the
difference in the cumulative dose of Clb in
MaBLe and CLL11. However, we do not believe
that this solely explains the discrepancies seen
in median PFS between the two R-Clb arms from
MaBLe and CLL11, since there is evidence
which points against ‘Clb dosing’ as an effect
modifier of PFS [27, 34, 35]. Admittedly, there is
still some debate around the role of Clb dosing
on PFS.
The results of our NMA should ideally be
validated in independent studies, and our
findings should be interpreted taking into
account a number of limitations. First, a
limited number of studies were eligible for
inclusion in the analysis. Many of the
comparisons were informed by a single trial
(e.g., CLL11 was the only trial to compare G-Clb
and R-Clb). This limited the statistical
assessment of heterogeneity and inconsistency
and also precluded the performance of more
sophisticated analyses, for example,
meta-regression to adjust for potential effect
modifiers. Our selection strategy (five criteria
and expert opinion) also aimed at increasing
the homogeneity of the trials in the network.
Nonetheless, the levels of unfitness still varied
among the selected trials, which could
ultimately have influenced our NMA. Second,
the follow-up times for OS (and to a lesser
extent PFS) were relatively short; longer
follow-up would likely have impacted on the
effect size, especially the CrIs. Third, in two
trials, assumptions were required to calculate
lnHR and SD, and these estimates may have
differed from the estimate of HR using whole
Kaplan–Meier curves.
Our results are comparable with the findings
reported by Ladyzynski et al. [16] in their recent
NMA of first-line treatment for CLL. Using a
Bayesian NMA, they compared the effectiveness
of available therapies in terms of PFS and OS in
patients with treatment-naı¨ve symptomatic
CLL and in subgroups of younger/fit and
older/unfit patients (median age C69 years). Of
the five treatments evaluated in older/unfit
patients (Clb, F, O-Clb, G-Clb, and R-Clb),
G-Clb was associated with longer projected
mean PFS versus all other comparators
(60 months versus 16–30 months) and had the
highest potential of increasing OS (90 months
versus 44–59 months). Also, corresponding
median hazard rates for G-Clb were the lowest
of all the analyzed treatment options (PFS\0.05
over 120 months; OS \0.01 during the initial
65 months of survival). Of note, this analysis
differed from our own NMA in a number of
respects: it stipulated stricter study eligibility
criteria (all included RCTs were required to
provide a survival curve); an overall analysis (no
restriction on fitness); and separate analyses for
fit and unfit were performed, whereas our focus
was on the unfit setting only; older/unfit was
defined as median age C69 years or median
CIRS C8, whereas we used five criteria; and the
MaBLe study was not included.
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The results of a second NMA evaluating US
Food and Drug Administration/European
Medicines Agency-approved treatment options
for previously untreated patients with CLL
ranked RFC highest in terms of efficacy, while
all single agents (with the exception of Alm)
occupied the worst ranks [19]. Unlike our NMA,
the authors imposed no restrictions in terms of
physical fitness or age of the study participants,
and full-dose F studies were also included.
Furthermore, the analysis did not include
important recent trials, for example, CLL11
(G-Clb), MaBLe (R-Benda), and Complement 1
(O-Clb). In an earlier study, Cheng et al. [36]
also used similar NMA methodology to analyze
treatments that had not been directly compared
in terms of PFS in previously untreated patients
with CLL. The findings suggested that RFC
achieved relatively longer PFS compared with
FC, F, Alm, and Clb (76 months versus
23–60 months); however, the data were
limited to younger patients (59–65 years) with
good performance status and early-stage disease
[36]. In a multiple-treatment meta-analysis
using direct and indirect data based on all
available head-to-head RCTs, Terasawa et al.
[37] concluded that there was insufficient
evidence on OS to recommend a specific
first-line treatment for CLL and that any
observed PFS differences may have been
attributable to the relatively young
uncomplicated patient populations.
Our NMA suggests that G-Clb is an effective
treatment for unfit patients with CLL, with
suggestion of superiority over R-Benda and
RFC-Lite, accepting the limitations discussed
elsewhere in this manuscript. Previously, the
MaBLe study showed that using Benda instead
of Clb as the backbone of
immunochemotherapy for unfit patients with
CLL improves efficacy [10]. In addition, the
ongoing GREEN study (NCT01905943) has
reported preliminary safety and efficacy data
for obinutuzumab in combination with
bendamustine (G-Benda), also in the patient
subset of unfit CLL [38]. A potential future
therapeutic intervention for unfit patients with
CLL that was not considered in our NMA is
ibrutinib, a first-in-class oral inhibitor of
Bruton’s tyrosine kinase which is a key
mediator of B-cell signaling [39, 40]. Ibrutinib
was recently licensed for the treatment of adult
patients with previously untreated CLL,
including those aged C65 years. In a final
analysis of the phase III RESONATE-2 trial,
ibrutinib was reported to significantly improve
PFS and OS compared with Clb in previously
untreated patients with CLL (n = 269; PFS
median not reached versus 18.9 months, HR
0.16, 95% CI 0.09–0.28, P\0.0001; OS median
not reached for either arm, HR 0.16, 95% CI
0.05–0.56, P = 0.0010). Patients were aged C65
years, approximately 30% had a CIRS score[6,
and the median European Cooperative
Oncology Group status was 0, thus the
majority of patients were closer to the
populations in the CLL8 and CLL10 trials than
to the population in CLL11 [40]. In addition,
Ibrutinib is also under evaluation in the unfit
setting in combination with G-Benda
(CLL2-BIG trial, Clinical Trials.gov identifier,
NCT02345863) [41]. Pyruvate dehydrogenase
kinase (PDK) inhibitors [42] and other
inhibitors of the B-cell receptor (BCR) pathway
[43] are also in development for the treatment
of CLL. However, PDK inhibitor development is
still at a very early stage, and following initial
promising efficacy results for idelalisib, studies
of first-line use have been halted due to severe
immune-mediated toxicities, and further safety
data are now required [44]. We are not aware of
any information regarding the availability and
affordability of these compounds in the patient
population considered for this NMA.
1826 Adv Ther (2016) 33:1814–1830
The goal of the current study was to inform
on the efficacy of commercially available drugs
for the treatment of unfit patients with CLL.
Although economic factors play a key role in
shaping healthcare decision-making, the
consideration of drug costs and treatment
outcomes was beyond the scope of the current
study. For this reason, information on the
cost-effectiveness of the different treatment
options for unfit patients with CLL requires
careful evaluation in subsequent publications
and/or health technology assessment
submissions. Furthermore, while
considerations of effectiveness may be
applicable across different healthcare systems,
considerations of costs and values are more
likely to be healthcare system-specific.
Therefore, a cost-effectiveness guideline may
be less transferable across countries than one
based on clinical effectiveness [45].
CONCLUSIONS
Results from our NMA demonstrate a clear
preference in terms of PFS for G-Clb versus
R-Clb, O-Clb, fludarabine and chlorambucil,
and a trend for better efficacy versus R-Benda
and RFC-Lite. A higher degree of uncertainty
was associated with the OS results, but the
findings were generally consistent with PFS
data. Together, these data support the
conclusion that G-Clb is an effective first-line
treatment for unfit patients with CLL and is
likely to show superior efficacy compared with
other treatment options.
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